Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection.

Abstract

A 31-year-old, obese woman with extrameningeal cryptococcal disease was admitted to the Medical College of Virginia for antifungal therapy. Various physiologic variables influence flucytosine pharmacokinetics, and there are no guidelines for dosing the agent in obese patients. This patient received a dosage based on her ideal body weight, and serum drug concentrations were monitored. She recovered without sequelae.

• Authors: J G Gillum, M Johnson, S Lavoie, J Venitz
• Journal: Pharmacotherapy (Pharmacotherapy) 1995 Mar-Apr Vol. 15 Issue 2 Pg. 251-3 ISSN: 0277-0008 [Print] United States
• PMID: 7624273 (Publication Type: Case Reports, Journal Article)

Chemical References

• Amphotericin B
• Flucytosine

Topics

• Adult
• Amphotericin B (administration & dosage, pharmacokinetics, therapeutic use)
• Cryptococcosis (complications, drug therapy, metabolism)
• Dermatomycoses (complications, drug therapy, metabolism)
• Female
• Flucytosine (administration & dosage, pharmacokinetics, therapeutic use)
• Humans
• Obesity, Morbid (complications, metabolism)